Citations per year, relative to I Balažovjech I Balažovjech (= 1×)
peers
A. Efstratopoulos
Countries citing papers authored by I Balažovjech
Since
Specialization
Citations
This map shows the geographic impact of I Balažovjech's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I Balažovjech with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I Balažovjech more than expected).
This network shows the impact of papers produced by I Balažovjech. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I Balažovjech. The network helps show where I Balažovjech may publish in the future.
Co-authorship network of co-authors of I Balažovjech
This figure shows the co-authorship network connecting the top 25 collaborators of I Balažovjech.
A scholar is included among the top collaborators of I Balažovjech based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with I Balažovjech. I Balažovjech is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Balažovjech, I, et al.. (2003). The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial in Slovakia.. PubMed. 104(1). 19–26.2 indexed citations
5.
Balažovjech, I, et al.. (2003). Compliance and the therapeutic effect in patients with arterial hypertension.. PubMed. 104(4-5). 149–54.6 indexed citations
6.
Kettmann, R., K Hlubinová, I Balažovjech, et al.. (2001). Germline mutation of the RET proto-oncogene in members of Slovak families with multiple endocrine neoplasia 2.. PubMed. 48(6). 445–50.2 indexed citations
Widimský, J, I Balažovjech, & Věra Lánská. (1999). [The role of home pressure monitoring in the treatment hypertension in the practice of general medicine].. PubMed. 45(10). 569–77.
9.
Oravec, Stanislav, Karine Demuth, I. Myara, A Hornych, & I Balažovjech. (1998). [Atherogenic and anti-atherogenic plasma lipoproteins modulate secretion of prostanoids by endothelial cells in vitro].. PubMed. 99(10). 525–30.2 indexed citations
10.
Sadowski, Zygmunt, et al.. (1998). Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.. PubMed. 16(3). S55–62.13 indexed citations
Breza, J., et al.. (1996). Tumours of the adrenal cortex.. PubMed. 30(1). 26–32.1 indexed citations
13.
Dukát, Andrej & I Balažovjech. (1996). A 5-year follow-up of preventive approach to patients with essential hypertension.. PubMed. 10 Suppl 3. S131–3.1 indexed citations
14.
Balažovjech, I. (1995). [25 years' experience with diagnosis of pheochromocytoma].. PubMed. 41(8). 513–6.1 indexed citations
15.
Brandšteterová, E., et al.. (1994). HPLC-ED determination of catecholamines and their metabolites in urine.. PubMed. 41(4). 205–11.5 indexed citations
16.
Balažovjech, I & P Hnilica. (1993). Compliance with antihypertensive treatment in consultation rooms for hypertensive patients.. PubMed. 7(6). 581–3.50 indexed citations
17.
Balažovjech, I. (1992). [Psychosomatic aspects of arterial hypertension].. PubMed. 38(7). 711–4.
18.
Balažovjech, I, et al.. (1992). [Wilson's disease and pregnancy].. PubMed. 38(3). 276–80.1 indexed citations
Balažovjech, I, et al.. (1987). The effect of small doses of guanfacine (Estulic Sandoz) on the lipid levels and catecholamine excretion in patients with essential hypertension.. PubMed. 29(4 Suppl 1). 46–52.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.